Literature DB >> 19375814

Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung.

A Omlin1, G D'Addario, S Gillessen, T Cerny, A von Hessling, M Früh.   

Abstract

A 53-year-old woman was with adenocarcinoma of the lung metastatic to the brain was treated after several lines of chemotherapy with pemetrexed. After six cycles an impressive regression of the brain metastases was documented. A brief review of the literature on response of cerebral metastases to chemotherapy is added.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19375814     DOI: 10.1016/j.lungcan.2009.03.019

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  4 in total

1.  First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature.

Authors:  Chu Zhang; Feng-Wei Kong; Wen-Bin Wu; Miao Zhang; Guang-Mao Yu; Xiang Wang; Yuan-Yuan Liu
Journal:  Medicine (Baltimore)       Date:  2020-09-04       Impact factor: 1.889

2.  Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases.

Authors:  Priya Kumthekar; Sean A Grimm; Michael J Avram; Virginia Kaklamani; Irene Helenowski; Alfred Rademaker; Mary Cianfrocca; William Gradishar; Jyoti Patel; Mary Mulcahy; Katie McCarthy; Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2013-01-25       Impact factor: 4.130

3.  A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.

Authors:  Matthew A Gubens; Jody C Chuang; Wallace Akerley; Corey J Langer; Christelle Clément-Duchêne; Melanie San Pedro-Salcedo; A Dimitrios Colevas; Konstantin Dragnev; Mark A Socinski; Heather A Wakelee
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

4.  Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.

Authors:  Ying Yuan; Chunwen Tan; Modan Li; Hong Shen; Xuefeng Fang; Yinghong Hu; Shenglin Ma
Journal:  World J Surg Oncol       Date:  2012-11-07       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.